Top

Reviews in Endocrine and Metabolic Disorders

Published in:

01-06-2015

The PTH-Vitamin D-FGF23 axis

Authors: Jenny E. Blau, Michael T. Collins

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 2/2015

Abstract

Fibroblast growth factor 23 (FGF23) has emerged as an important regulator of phosphate and vitamin D homeostasis. It is important to understand how FGF23 interacts with vitamin D and parathyroid hormone (PTH) in a FGF23-Vitamin D-PTH axis to regulate mineral homeostasis. In this review, we discuss the genomic structure, and transcriptional, translational, and posttranslational regulation of FGF23. We describe its interaction with PTH and vitamin D, disorders of altered FGF23 states, and emerging therapies for diseases of FGF23 based upon these findings. This discussion helps redefine the role of PTH and vitamin D in relation to a complex bone-kidney-parathyroid loop, and points to areas within this complicated field in need of further clarification and research.

Prader A et al. [Rickets following bone tumor]. Helv Paediatr Acta. 1959;14:554–65.PubMed

Meyer Jr RA, Meyer MH, Gray RW. Parabiosis suggests a humoral factor is involved in X-linked hypophosphatemia in mice. J Bone Miner Res. 1989;4(4):493–500.PubMedCrossRef

White KE et al. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int. 2001;60(6):2079–86.PubMedCrossRef

White KE et al. The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab. 2001;86(2):497–500.PubMedCrossRef

ADHR C. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. The ADHR Consortium. Nat Genet. 2000;26(3):345–8.CrossRef

Shimada T et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A. 2001;98(11):6500–5.PubMedCentralPubMedCrossRef

Cai Q et al. Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. N Engl J Med. 1994;330(23):1645–9.PubMedCrossRef

Feng JQ et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet. 2006;38(11):1310–5.PubMedCentralPubMedCrossRef

Lorenz-Depiereux B et al. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet. 2006;38(11):1248–50.PubMedCrossRef

10.

Turan S et al. Identification of a novel dentin matrix protein-1 (DMP-1) mutation and dental anomalies in a kindred with autosomal recessive hypophosphatemia. Bone. 2010;46(2):402–9.PubMedCentralPubMedCrossRef

11.

Levy-Litan V et al. Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene. Am J Hum Genet. 2010;86(2):273–8.PubMedCentralPubMedCrossRef

12.

Saito T et al. A patient with hypophosphatemic rickets and ossification of posterior longitudinal ligament caused by a novel homozygous mutation in ENPP1 gene. Bone. 2011;49(4):913–6.PubMedCrossRef

13.

Carpenter TO et al. A clinician’s guide to X-linked hypophosphatemia. J Bone Miner Res. 2011;26(7):1381–8.PubMedCentralPubMedCrossRef

14.

Bhattacharyya N et al. Mechanism of FGF23 processing in fibrous dysplasia. J Bone Miner Res. 2012;27(5):1132–41.PubMedCrossRef

15.

Riminucci M et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest. 2003;112(5):683–92.PubMedCentralPubMedCrossRef

16.

Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun. 2000;277(2):494–8.PubMedCrossRef

17.

Bhattacharyya N et al. Fibroblast growth factor 23: state of the field and future directions. Trends Endocrinol Metab. 2012;23(12):610–8.PubMedCentralPubMedCrossRef

18.

Yamazaki Y et al. Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J Bone Miner Res. 2008;23(9):1509–18.PubMedCrossRef

19.

Goetz R et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol. 2007;27(9):3417–28.PubMedCentralPubMedCrossRef

20.

Gattineni J, Baum M. Genetic disorders of phosphate regulation. Pediatr Nephrol. 2012;27(9):1477–87.PubMedCentralPubMedCrossRef

21.

Shimada T et al. Targeted ablation of Ffg23 demonstrates an essential physiological role of FGF23 in pohsphate and vitamin D metabolism. J Clin Invest. 2004;113(4):561–8.PubMedCentralPubMedCrossRef

22.

Shimada T et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19(3):429–35.PubMedCrossRef

23.

Weinman EJ et al. Fibroblast growth factor-23-mediated inhibition of renal phosphate transport in mice requires sodium-hydrogen exchanger regulatory factor-1 (NHERF-1) and synergizes with parathyroid hormone. J Biol Chem. 2011;286(43):37216–21.PubMedCentralPubMedCrossRef

24.

Baum M et al. Effect of fibroblast growth factor-23 on phosphate transport in proximal tubules. Kidney Int. 2005;68(3):1148–53.PubMedCrossRef

25.

Farrow EG et al. Initial FGF23-mediated signaling occurs in the distal convoluted tubule. J Am Soc Nephrol. 2009;20(5):955–60.PubMedCentralPubMedCrossRef

26.

Andrukhova O et al. FGF23 acts directly on renal proximal tubules to induce phosphaturia through activation of the ERK1/2-SGK1 signaling pathway. Bone. 2012;51(3):621–8.PubMedCentralPubMedCrossRef

27.

Ben-Dov IZ et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest. 2007;117(12):4003–8.PubMedCentralPubMed

28.

Krajisnik T et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol. 2007;195(1):125–31.PubMedCrossRef

29.

Ichikawa S et al. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Clin Invest. 2007;117(9):2684–91.PubMedCentralPubMedCrossRef

30.

Brownstein CA et al. A translocation causing increased alpha-klotho level results in hypophosphatemic rickets and hyperparathyroidism. Proc Natl Acad Sci U S A. 2008;105(9):3455–60.

31.

Chong WH et al. Tumor-induced osteomalacia. Endocr Relat Cancer. 2011;18(3):R53–77.PubMedCentralPubMedCrossRef

32.

Smith ER et al. Biological variability of plasma intact and C-terminal FGF23 measurements. J Clin Endocrinol Metab. 2012;97(9):3357–65.PubMedCrossRef

33.

Jonsson KB et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med. 2003;348(17):1656–63.PubMedCrossRef

34.

Lorenz-Depiereux B et al. Hereditary hypophosphatemic rickets with hypercalciuria is caused by mutations in the sodium-phosphate cotransporter gene SLC34A3. Am J Hum Genet. 2006;78(2):193–201.PubMedCentralPubMedCrossRef

35.

Nishida Y, et al. Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men. Kidney Int. 2006.

36.

Larsson T et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 2003;64(6):2272–9.PubMedCrossRef

37.

Burnett SM et al. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res. 2006;21(8):1187–96.PubMedCrossRef

38.

Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab. 2005;90(3):1519–24.PubMedCrossRef

39.

Antoniucci DM, Yamashita T, Portale AA. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab. 2006;91(8):3144–9.PubMedCrossRef

40.

Perwad F et al. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology. 2005;146(12):5358–64.PubMedCrossRef

41.

Scanni R et al. The human response to acute enteral and parenteral phosphate loads. J Am Soc Nephrol. 2014;25(12):2730–9.PubMedCrossRef

42.

Quinn SJ et al. Interactions between calcium and phosphorus in the regulation of the production of fibroblast growth factor 23 in vivo. Am J Physiol Endocrinol Metab. 2013;304(3):E310–20.PubMedCentralPubMedCrossRef

43.

Lavi-Moshayoff V et al. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol. 2010;299(4):F882–9.PubMedCrossRef

44.

Lopez I et al. Direct and indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo. Kidney Int. 2011;80(5):475–82.PubMedCrossRef

45.

Liu S et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol. 2006;17(5):1305–15.PubMedCrossRef

46.

Saji F et al. Regulation of fibroblast growth factor 23 production in bone in uremic rats. Nephron Physiol. 2009;111(4):59–66.CrossRef

47.

Samadfam R et al. Bone formation regulates circulating concentrations of fibroblast growth factor 23. Endocrinology. 2009;150(11):4835–45.PubMedCrossRef

48.

Burnett-Bowie SA et al. Effects of hPTH(1–34) infusion on circulating serum phosphate, 1,25-dihydroxyvitamin D, and FGF23 levels in healthy men. J Bone Miner Res. 2009;24(10):1681–5.PubMedCentralPubMedCrossRef

49.

Gutierrez OM et al. (1–34) Parathyroid hormone infusion acutely lowers fibroblast growth factor 23 concentrations in adult volunteers. Clin J Am Soc Nephrol. 2012;7(1):139–45.PubMedCentralPubMedCrossRef

50.

Singh RJ, Kumar R. Fibroblast growth factor 23 concentrations in humoral hypercalcemia of malignancy and hyperparathyroidism. Mayo Clin Proc. 2003;78(7):826–9.PubMedCrossRef

51.

Tebben PJ et al. Fibroblast growth factor 23, parathyroid hormone, and 1alpha,25-dihydroxyvitamin D in surgically treated primary hyperparathyroidism. Mayo Clin Proc. 2004;79(12):1508–13.PubMedCrossRef

52.

Kobayashi K et al. Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism. Eur J Endocrinol. 2006;154(1):93–9.PubMedCrossRef

53.

Kawata T et al. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol. 2007;18(10):2683–8.PubMedCrossRef

54.

Mosekilde L. Primary hyperparathyroidism and the skeleton. Clin Endocrinol (Oxf). 2008;69(1):1–19.CrossRef

55.

Brown WW et al. Hypophosphatemia with elevations in serum fibroblast growth factor 23 in a child with Jansen’s metaphyseal chondrodysplasia. J Clin Endocrinol Metab. 2009;94(1):17–20.PubMedCentralPubMedCrossRef

56.

Collins MT et al. Fibroblast growth factor-23 is regulated by 1alpha,25-dihydroxyvitamin D. J Bone Miner Res. 2005;20(11):1944–50.PubMedCrossRef

57.

Hill LF et al. Treatment of hypoparathyroidism with 1,25-dihydroxycholecalciferol. Clin Endocrinol (Oxf). 1976;5(Suppl):167S–73.CrossRef

58.

Yu X et al. Genetic dissection of phosphate- and vitamin D-mediated regulation of circulating Fgf23 concentrations. Bone. 2005;36(6):971–7.PubMedCrossRef

59.

Saito H et al. Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem. 2005;280(4):2543–9.PubMedCrossRef

60.

Ito M, et al. Vitamin D and phosphate regulate fibroblast growth factor-23 in K562 cells. Am J Physiol Endocrinol Metab. 2005.

61.

Dubois SG et al. Role of abnormal neutral endopeptidase-like activities in Hyp mouse bone cells in renal phosphate transport. Am J Physiol Cell Physiol. 2002;283(5):C1414–21.PubMedCrossRef

62.

Rowe PS. Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway. Crit Rev Eukaryot Gene Expr. 2012;22(1):61–86.PubMedCentralPubMedCrossRef

63.

Guo R et al. Inhibition of MEPE cleavage by Phex. Biochem Biophys Res Commun. 2002;297(1):38–45.PubMedCrossRef

64.

Benet-Pages A, et al. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet. 2004.

65.

Tagliabracci VS et al. Dynamic regulation of FGF23 by Fam20C phosphorylation, GalNAc-T3 glycosylation, and furin proteolysis. Proc Natl Acad Sci U S A. 2014;111(15):5520–5.PubMedCentralPubMedCrossRef

66.

Wang X et al. Inactivation of a novel FGF23 regulator, FAM20C, leads to hypophosphatemic rickets in mice. PLoS Genet. 2012;8(5), e1002708.PubMedCentralPubMedCrossRef

67.

Simpson MA et al. Mutations in FAM20C are associated with lethal osteosclerotic bone dysplasia (Raine syndrome), highlighting a crucial molecule in bone development. Am J Hum Genet. 2007;81(5):906–12.PubMedCentralPubMedCrossRef

68.

White KE et al. Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation. Am J Hum Genet. 2005;76(2):361–7.PubMedCentralPubMedCrossRef

69.

Wohrle S et al. Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. J Bone Miner Res. 2013;28(4):899–911.PubMedCrossRef

70.

Wohrle S et al. FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone. J Bone Miner Res. 2011;26(10):2486–97.PubMedCrossRef

71.

Zhang MY et al. Chronic inhibition of ERK1/2 signaling improves disordered bone and mineral metabolism in hypophosphatemic (Hyp) mice. Endocrinology. 2012;153(4):1806–16.PubMedCentralPubMedCrossRef

72.

Xiao Z et al. Osteocyte-specific deletion of Fgfr1 suppresses FGF23. PLoS One. 2014;9(8), e104154.PubMedCentralPubMedCrossRef

73.

Han X, Xiao Z, Quarles LD. Membrane and integrative nuclear fibroblastic growth factor receptor (FGFR) regulation of FGF-23. J Biol Chem. 2015;290(16):10447–59.PubMedCrossRef

74.

Liu S et al. Novel regulators of Fgf23 expression and mineralization in Hyp bone. Mol Endocrinol. 2009;23(9):1505–18.PubMedCentralPubMedCrossRef

75.

Xiao L, Esliger A, Hurley MM. Nuclear fibroblast growth factor 2 (FGF2) isoforms inhibit bone marrow stromal cell mineralization through FGF23/FGFR/MAPK in vitro. J Bone Miner Res. 2013;28(1):35–45.PubMedCentralPubMedCrossRef

76.

Lee JC et al. Identification of a novel FN1-FGFR1 genetic fusion as a frequent event in phosphaturic mesenchymal tumour. J Pathol. 2015;235(4):539–45.PubMedCrossRef

77.

Jacob AL et al. Fibroblast growth factor receptor 1 signaling in the osteo-chondrogenic cell lineage regulates sequential steps of osteoblast maturation. Dev Biol. 2006;296(2):315–28.PubMedCentralPubMedCrossRef

78.

Beighton P, Cremin BJ, Kozlowski K. Osteoglophonic dwarfism. Pediatr Radiol. 1980;10(1):46–50.PubMedCrossRef

79.

Geller JL et al. Cinacalcet in the management of tumor-induced osteomalacia. J Bone Miner Res. 2007;22(6):931–7.PubMedCrossRef

80.

Alon US et al. Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets. Clin J Am Soc Nephrol. 2008;3(3):658–64.PubMedCentralPubMedCrossRef

81.

Aono Y et al. Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J Bone Miner Res. 2009;24(11):1879–88.PubMedCrossRef

82.

Carpenter TO et al. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J Clin Invest. 2014;124(4):1587–97.PubMedCentralPubMedCrossRef

83.

Shigematsu T et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis. 2004;44(2):250–6.PubMedCrossRef

84.

Gutierrez O et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005;16(7):2205–15.PubMedCrossRef

85.

Gutierrez OM et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359(6):584–92.PubMedCentralPubMedCrossRef

86.

Gutierrez OM et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation. 2009;119(19):2545–52.PubMedCentralPubMedCrossRef

87.

Faul C et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121(11):4393–408.PubMedCentralPubMedCrossRef

88.

Desjardins L et al. FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos Int. 2012;23(7):2017–25.PubMedCrossRef

89.

Srivaths PR et al. Elevated FGF 23 and phosphorus are associated with coronary calcification in hemodialysis patients. Pediatr Nephrol. 2011;26(6):945–51.PubMedCrossRef

90.

Roos M et al. Relation between plasma fibroblast growth factor-23, serum fetuin-A levels and coronary artery calcification evaluated by multislice computed tomography in patients with normal kidney function. Clin Endocrinol (Oxf). 2008;68(4):660–5.CrossRef

91.

Inaba M et al. Role of fibroblast growth factor-23 in peripheral vascular calcification in non-diabetic and diabetic hemodialysis patients. Osteoporos Int. 2006;17(10):1506–13.PubMedCrossRef

92.

Feldman HI et al. The chronic renal insufficiency cohort (CRIC) study: design and methods. J Am Soc Nephrol. 2003;14(7 Suppl 2):S148–53.PubMedCrossRef

93.

Isakova T et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011;79(12):1370–8.PubMedCentralPubMedCrossRef

94.

Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int. 2012;82(7):737–47.PubMedCentralPubMedCrossRef

95.

Hasegawa H et al. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int. 2010;78(10):975–80.PubMedCrossRef

96.

Shalhoub V et al. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest. 2012;122(7):2543–53.PubMedCentralPubMedCrossRef

Title: The PTH-Vitamin D-FGF23 axis
Authors: Jenny E. Blau
Michael T. Collins
Publication date: 01-06-2015
Publisher: Springer US
Published in: Reviews in Endocrine and Metabolic Disorders / Issue 2/2015
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI: https://doi.org/10.1007/s11154-015-9318-z

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2015

RANKL/OPG; Critical role in bone physiology

LRP receptor family member associated bone disease

The dynamic skeleton

An overview of the metabolic functions of osteocalcin

Bone kidney interactions

Bone, brain & beyond

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage